The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance

Patricia Maiso, Xonia Carvajal-Vergara, Enrique M. Ocío, Ricardo López-Pérez, Gema Mateo, Norma Gutiérrez, Peter Atadja, Atanasio Pandiella, and Jesús F. San Miguel

Abstract

Multiple myeloma represents an incurable disease, for which development of new therapies is required. Here, we report the effect on myeloma cells of LBH589, a new hydroxamic acid–derived histone deacetylase inhibitor. LBH589 was a potent antimyeloma agent (IC50 < 40 nmol/L) on both cell lines and derived histone deacetylase inhibitor. LBH589 was a potent effect on myeloma cells of LBH589, a new hydroxamic acid–derived histone deacetylase inhibitor. LBH589 was a potent antimyeloma agent (IC50 < 40 nmol/L) on both cell lines and fresh cells from multiple myeloma patients, including cells resistant to conventional chemotherapeutic agents. In addition, LBH589 potentiated the action of drugs, such as bortezomib, dexamethasone, or melphalan. Using gene array, quantitative PCR, and Western analyses, we observed that LBH589 affected a large number of genes involved in cell cycle and cell death pathways. LBH589 blocked cell cycle progression, and this was accompanied by p21, p53, and p57 up-regulation. LBH589 induced cell death through an increase in the mitochondrial outer membrane permeability. LBH589 favored apoptosis formation by inducing cytochrome c release, Apaf-1 up-regulation, and caspase-9 cleavage. In addition, LBH589 stimulated a caspase-independent pathway through the release of AIF from the mitochondria. LBH589 down-regulated Bcl-2 and particularly Bel-X. Moreover, over-expression of Bel-X in multiple myeloma cells prevented LBH589-induced cell death. All these data indicate that LBH589 could be a useful drug for the treatment of multiple myeloma patients. (Cancer Res 2006; 66(11): 5781-9)

Introduction

New anticancer treatment strategies focus on targeting intrinsic molecular mechanisms of tumor cells, which could offer higher efficacy with less adverse effects. One of these novel anticancer family drugs, which provided promising results, are histone deacetylase (HDAC) inhibitors (1–3). Histone acetylation is presumed to be an important factor that regulates the accessibility of transcription factors to DNA (1, 2, 4). The presence of acetyl groups neutralizes the positive charges of the histones, therefore decreasing their interaction with DNA. By removing the acetyl groups, HDACs facilitate the interaction of histones with the DNA (1, 2).

Analyses on the mechanisms of HDAC inhibitor–induced cell death have indicated that these compounds may act by blocking cell cycle progression and inducing cell death (1, 2, 5). Despite the consensus on the importance of apoptosis in the effect of these drugs, the contribution of caspases to this cell death is quite controversial (5–9). In this sense, some studies have described activation of caspases (5, 7, 9, 10), whereas others advocate a caspase-independent apoptosis (6, 8). Moreover, attempts to block HDAC inhibitor–associated apoptosis with a pancaspase inhibitor (Z-VAD-FMK) have usually been ineffective (5–8), suggesting that caspase activation is not critical in HDAC inhibitor–induced apoptosis. A quite common finding in all studies has been the involvement of Bcl-2 family members in the action of HDAC inhibitor (5, 6, 8, 9, 11). Thus, cleavage of the BH3-only proapoptotic Bcl-2 family member Bid (5, 6, 8, 9), associated with mitochondrial disruption or down-regulation of Bcl-2 or Bcl-X, which act as an antiapoptotic factor, has been reported (8, 9, 11). Another mechanism proposed to be involved in the cell death caused by HDAC inhibitors has been autophagy (7).

Despite novel therapeutic strategies introduced in the treatment armamentarium of multiple myeloma, it remains an incurable disease. Therefore, new drugs are needed to improve the outcome of these patients (12). HDAC inhibitors of the hydroxamic acid family, such as SAHA (6, 13) or NVP-LAQ824 (14), have been shown to possess antimyeloma activity. However, their potency is low, as they are only effective at micromolar concentrations (6, 14). Attempts to improve the potency of HDAC inhibitor led to the development of a novel class of cinnamic acid hydroxamates that act on cells at nanomolar concentrations. One of these compounds, LBH589, has shown promising results in myeloid leukemias at low nanomolar concentrations (15). In the present study, we have analyzed the action of LBH589 on multiple myeloma cell lines and freshly isolated cells from multiple myeloma patients. Our results show that LBH589 significantly inhibited growth of multiple myeloma cells and enhanced the cytotoxicity triggered by dexamethasone, melphalan, and bortezomib. LBH589 induced cell cycle arrest and apoptosis of multiple myeloma cells, the latter involving both caspase-dependent and caspase-independent pathways. Furthermore, gene expression results uncovered a group of proteins, such as Även (16) and Toso (17–19), which may play a relevant role in multiple myeloma apoptosis.

Materials and Methods

Reagents and immunochemicals. Cell culture media, serum, and penicillin-streptomycin were from Invitrogen Corp. (Gaithersburg, MD). LBH589 was provided by Novartis Pharmaceuticals (East Hanover, NJ), and bortezomib was from Millenium Pharmaceuticals (Cambridge, MA). Annexin V-FITC was obtained from BD Biosciences (San Diego, CA). Calpeptin and Z-VAD-FMK were from Calbiochem (San Diego, CA). Other generic chemicals were purchased from Sigma Chemical Co. (St. Louis, MO), Roche Biochemicals (Mannheim, Germany), or Merck (Darmstadt, Germany).

The origins of the different antibodies employed in the Western blotting analyses were as follows: the anti-p21, anti-phospho extracellular...
signal-related kinase (anti-pErk), anti-Erk1/2, anti-caspase-3 were from Santa Cruz Biotechnology (Santa Cruz, CA); the anti-Apaf-1, anti-caspase-8, -caspase-9, -cytochrome c, -anti-AIF, anti-Bcl-X, -anti-poly(ADP-ribose) polymerase (anti-PARP), -anti-Bcl-2, -anti-cyclin-dependent kinase 4 (anti-Cdk4), -anti-cyclin D1, and -anti-Bid antibodies were from BD Biosciences. The anti-p53 antibody was from Oncogene Science (Uniondale, NY). The anti-acetyl-Histone H4 was from Cell Signaling (Beverly, MA). The anti-actin antibody was from Sigma (St. Louis, MO). The horseradish peroxidase–conjugated secondary antibodies were from Bio-Rad (Richmond, CA).

**Cell cultures.** All multiple myeloma cell lines (MM1S, MM1R, U266, U266LR7, and U266DOX4) were cultured at 37°C in a humidified atmosphere in the presence of 5% CO2/95% air. The source of the multiple myeloma cell lines has been described previously (20). Cell lines and bone marrow cells obtained from four multiple myeloma patients were cultured in RPMI 1640 with -glutamine and supplemented with antibiotics (penicillin at 100 units/mL, streptomycin at 100 μg/mL) and 10% fetal bovine serum (FBS) for cell lines or 20% FBS for patient cells.

**Cell proliferation, cell cycle, and apoptosis assays.** The proliferation of multiple myeloma cells was examined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assays as described (20). For cell cycle analyses, the CD38-CD138/propidium iodide double-staining technique was used (21). For cytometric evaluation of apoptosis in multiple myeloma cell lines, one million MM1S cells were washed with PBS and resuspended in binding buffer (10 mmol/L HEPES/NaOH (pH 7.4), 140 mmol/L NaCl, 2.5 mmol/L CaCl2). Cells were incubated with 5 μL Annexin V-FITC for 10 minutes at room temperature in the dark, and then 10 μL propidium iodide were added. For cytometric analyses of apoptosis in bone marrow cell subpopulations from patients, the unseparated bone marrow samples were lysed and maintained in RPMI 1640 containing 20% FBS. Subsequently, the bone marrow cells were incubated with the different drugs in six-well plates during 18 hours at 37°C. To discriminate between myelomatous plasma cells and apoptotic residual bone marrow cells, we did a multiparametric technique based on the combination of Annexin V-FITC and four-color monoclonal antibodies against myeloma-associated antigens (CD38, CD56, CD28, and CD45). The use of the first three monoclonal antibodies allows the identification of plasma cells, displaying different phenotypic aberrations, whereas CD45 contributes to the identification of other hematopoietic populations. Briefly, cells were incubated for 15 minutes at room temperature in the dark with 5 μL Annexin V-FITC (Bender MedSystems, Burlingame, CA) together with a combination of monoclonal antibodies: anti-CD28-PE or anti-CD56-PE, anti-CD38-perCP/Cy5 (Cytognost, Salamanca, Spain) and anti-CD45-APC (BD Biosciences). A total of 50,000 cells were acquired on a FACS calibur flow cytometer (BD Biosciences) and analyzed with the Paint-A-Gate program. Plasma cells were identified based on their antigenic expression, and the percentage of Annexin V–positive fraction was calculated. Simultaneously, positivity of Annexin V in CD45+ positive cells (lymphocytes) and in SSCChigh positive, CD36moderate–positive, and CD45moderate positive cells (granulocytes) was evaluated as a reference for LHBS89 cytotoxicity on normal lymphocytes and granulocytes present in the same sample.

To qualitatively evaluate the mitochondrial transmembrane potential (∆Ψm), cells were incubated in PBS with 20 nmol/L 3,3′-dihexyloxacarbocyanine iodide [DiOC6(3); Molecular Probes, Leiden, the Netherlands] for 20 minutes at 37°C, washed with PBS, and 10 μL propidium iodide (Calbiochem) were added followed by fluorescence-activated cell sorting analysis (22).

**Microarray RNA analyses.** Time course experiments carried out in MM1S cells to delineate the onset of apoptosis showed that 15 hours was sufficient to induce the early steps of apoptosis (15-20% cell death assessed by Annexin V-FITC staining). At this time point, total RNA was extracted using Trizol reagent (Life Technologies, Gaithersburg, MD) and purified with RNeasy Mini kit (Qiagen, Carlsbad, CA). The RNA integrity was assessed using Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA). Double-stranded cDNA and biotinylated cDNA were synthesized using a T7-poly-T primer and the BioArray RNA labeling kit (Enzo, Farmingdale, NY), respectively. The labeled RNA was then fragmented and hybridized to HU-133A oligonucleotide arrays (Affymetrix, Santa Clara, CA). The arrays were scanned using the Gene Array Scanner and analyzed using the DNA-Chip Analyzer (DChip). Genes with expression changes ≥2-fold in either direction were considered significant.

**Reversal transcription-PCR and quantitative PCR.** RNA isolated from MM1S cells was primed with poly-T, and cDNA was synthesized with SuperScript II RNase H-Reverse transcriptase (Invitrogen). The relative levels of gene expression were determined by real-time quantitative PCR based on a two-step SYBR green I chemistry. As a reference, we used GAPDH. The primers were designed using the Primer Express software (Applied Biosystems, Foster City, CA). The sequence of the primers is available upon request.

**Western blotting.** Cells were collected and centrifuged at 10,000 × g for 2 minutes. Then cells were washed with PBS and lysed in ice-cold lysis buffer [140 mmol/L NaCl, 10 mmol/L EDTA, 10% glycerol, 1% NP40, 20 mmol/L Tris (pH 7), 1 μmol/L pepstatin, 1 μg/mL aprotinin, 1 μg/mL leupeptin, 1 mmol/L sodium orthovanadate]. Samples were centrifuged at 10,000 × g at 4°C for 10 minutes, and supernatants were transferred to new tubes with the corresponding antibody and protein A-Sepharose. Immuno-precipitations and Western blotting were done as described (20).

**Subcellular fractionation.** MM1S cells were harvested in isotypic mitochondrial buffer (ref. 23; 250 mmol/L sucrose, 20 mmol/L HEPES, 10 mmol/L KCl, 1.5 mmol/L MgCl2, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L DTT, 1 μmol/L pepstatin, 1 μg/mL aprotinin, 1 μg/mL leupeptin, 1 mmol/L sodium orthovanadate) and Dounce homogenized by 60 to 70 strokes. S100 samples were transferred to Eppendorf tubes and centrifuged at 770 × g for 10 minutes at 4°C to separate nuclei and unbroken cells. The resulting supernatant was centrifuged at 10,000 × g for 25 minutes at 4°C to obtain the mitochondrial pellet. The supernatant was further centrifuged at 100,000 × g for 1 hour at 4°C to yield the final soluble cytosolic fraction.

**Plasmids, generation of retroviruses, and infection.** Matrix metalloproteinase-1 (MMP-1) and MMP-1-A11-Bcl-X were generously provided by Dr. R. Mulligan (Harvard Medical School, Boston, MA). For transient generation of retroviruses, we used a previously published protocol (20). Forty-eight hours after infection, multiple myeloma cells were analyzed for infected protein content by Western blotting.

**Results**

**LHBS89 induces histone acetylation in myeloma cells.** To verify whether LHBS89 induced hyperacetylation of histones in myeloma, MM1S cells were treated with LBH589 for different times and concentrations of the compound, and histone H4 acetylation analyzed by Western blotting. MM1S cells exhibited a progressive increase in histone H4 acetylation correlating with the time and the dose of LBH589 (Fig. 1A). Treatment of MM1S cells with other compounds (melphalan, doxorubicin, and bortezomib) used in the therapy of myeloma (12, 24) indicated the specificity of the action of LBH589 on histone acetylation (Fig. 1B). Interestingly, melphalan and bortezomib also provoked a small increase in the acetylation of histone H4, although to a much lesser extent than LBH589.

**LHBS89 is a potent antimyeloma agent and overcomes drug resistance.** To investigate the effect of LHBS89 on growth and survival of multiple myeloma cells, we first used MTT assays on five different representative multiple myeloma cell lines, including sensitive and resistant to dexamethasone (MM1S and MM1R, respectively), sensitive and resistant to melphalan (U266 and U266LR7, respectively), and sensitive to doxorubicin (U266DOX4). Treatment with increasing doses of LBH589 (0.1-100 nmol/L) for 48 hours, potently suppressed MTT uptake (Fig. 1C). IC50 values for these cell lines were 5.7 nmol/L (MM1S), 6.5 nmol/L (MM1R), 8.1 nmol/L (U266), 24 nmol/L (U266LR7), and 45.5 nmol/L (U266DOX4). Comparison of the IC50 of LHBS89 with other drugs...
commonly used in multiple myeloma indicated that LBH589 was slightly less potent than bortezomib (IC50 = 2.4 nmol/L for MM1S cells) but was more potent than revlimid, dexamethasone, melphalan, doxorubicin, or arsenic trioxide (data not shown). The action of LBH589 on MM1S cells was also time dependent (Fig. 1D).

LBH589 was also tested on fresh bone marrow cells obtained from four multiple myeloma patients. Two of these patients (patients 1 and 2) were refractory to several lines of treatment (high-dose dexamethasone, alkylating agents and doxorubicin, and autologous stem cell transplantation, but they were not treated with bortezomib), whereas the remaining two patients (patients 3 and 4) were analyzed at diagnosis. As shown in Fig. 2A, all patients analyzed were sensitive to LBH589, even at the lowest dose (10 nmol/L) of the drug. Moreover, an apparent dose-response effect could be observed. One relevant finding was the low toxicity of LBH589 on the normal lymphocytes present in the same samples: no cytotoxicity was induced by LBH589 at 10 nmol/L, and only a minor increase in apoptotic cells was observed upon using 100 nmol/L of LBH589 (Fig. 2A). We also analyzed the effect of LBH589 on bone marrow myeloid cells. The cytotoxic effect of LBH589 on myeloid cells was slightly higher than in lymphocytes but markedly less than on malignant plasma cells (Fig. 2A).

**LBH589 increases the antimyeloma action of bortezomib, dexamethasone, and melphalan.** Because LBH589 acted on myeloma cells resistant to conventional antimyeloma treatments, the possibility that LBH589 could increase the action of those compounds was contemplated. To analyze this, MM1S cells were treated with combinations of LBH589 and several chemotherapeutic agents commonly used in multiple myeloma, as well as novel drugs. As shown in Fig. 2B, LBH589 was found to increase the antimyeloma effect of bortezomib, dexamethasone, or melphalan. However, LBH589 at concentrations as 0.1, 1, and 3 nmol/L did not enhance the ability of doxorubicin, revlimid, arsenic trioxide, or 5-aza-2′-deoxycytidine to inhibit MM1S cell proliferation (data not shown). We failed to observe any significant difference when LBH589 was added first, concomitantly, or subsequently to the other drugs (data not shown).

We also tested in fresh cells from four multiple myeloma patients the combination of LBH589 at 10 nmol/L with bortezomib (5 nmol/L). As illustrated in Fig. 2C, based on Annexin V staining, an additive effect was observed when LBH was combined with bortezomib compared with any of these two drugs used alone.

**LBH589 provokes cell cycle arrest in multiple myeloma cells.** The decrease in MTT uptake observed in multiple myeloma cells treated with LBH589 could be due to decreased proliferation, cell death, or both. To gain insights into the mechanism of action of LBH589 on multiple myeloma cells, we did gene expression analyses, complemented with biochemical and functional studies of cellular proteins involved in the regulation of cell cycle and survival routes.

Gene expression profiles of MM1S cells identified a total of 1,120 genes to be significantly deregulated (transcriptional changes in gene expression of ≥2-fold) by treatment with LBH589. The classification of these genes according to functional categories indicated that 9% were involved in apoptosis/responses to stress, 12% were involved in the control of cell cycle/proliferation, 18% were kinases that participate in cell cycle and survival signaling, 3% participated in adhesion, and 2% were involved in chromosome segregation/maintenance (Fig. 3A). These results indicated that
genes involved in cell cycle and cell death regulation were important targets for LBH589.

Analysis of the cell cycle distribution of MM1S cells after treatment with LBH589 showed that this drug caused an increase in G0-G1 and a decrease in S and G2-M (Fig. 3B). Progression of cells into the S phase is controlled by the Cip/Kip family of cell cycle regulators p21, p27, and p57 (25). Western blotting analyses of MM1S cells treated with LBH589 for different times indicated that this compound increased the levels of p21 after 3 hours of treatment (Fig. 3C). The increased amount of p21 correlated with a parallel increase in p53, which transcriptionally regulates p21 levels (26). Gene expression analyses confirmed the p21 Western blotting data and, in addition, showed that LBH589 up-regulated the levels of p57 (fold change = 6; Fig. 3D). Western blotting also showed that LBH589 decreased the levels of cyclin D1 and Cdk4 (Fig. 3C). In addition, microarray data showed that LBH589 down-regulated several other genes required for cell proliferation (CDC25A, CCND2, MCM-5, and Ki-67). LBH589 did not affect the phosphorylation status of Erk1/2 (Fig. 3C), an important route linked to multiple myeloma proliferation (27).

**LBH589 causes apoptosis in multiple myeloma cells.** Several already mentioned evidences indicated that cell death could represent an important consequence of LBH589 treatment. These include (a) the high number of apoptotic genes deregulated by LBH589, (b) the Annexin V data obtained in myeloma cells (Fig. 4A), and (c) the increase in the amount of the cells in the sub-G0-G1 region (from 3% to 11%). Furthermore, treatment with LBH589 caused internucleosomal DNA fragmentation, a hallmark of apoptosis (Fig. 4B). The degree of this effect was within the range of action of bortezomib, a potent inducer of apoptosis in multiple myeloma cells (28) that we used as a reference. As mitochondria seems to be an organelle critically involved in the triggering of apoptotic cell death (29), we explored whether LBH589 altered mitochondrial membrane potential (ΔΨm). Analysis of ΔΨm by the use of the mitochondrial membrane potential probe DioC6(3) showed a decrease in ΔΨm in cells treated with LBH589 (Fig. 4C).

**LBH589 causes caspase-dependent and caspase-independent cell death.** Loss of ΔΨm often reflects increases in mitochondrial outer membrane permeability, which results in the release of proteins that trigger cell death (29). One of these proteins is cytochrome c that together with caspase-9 and Apaf-1 constitute the apoptosome, a macromolecular structure that causes activation of the effector caspase-3 (29). In addition to cytochrome c, increases in mitochondrial outer membrane permeability also favor the release of AIF and endonuclease G, two other mediators of apoptosis (30). Subcellular fractionation of MM1S cells treated for various times with LBH589 showed that this drug caused a time-dependent translocation of cytochrome c and AIF from the mitochondrial to the cytosolic fraction (Fig. 4D). Another component of the apoptosome (Apaf-1) was up-regulated, as determined by Western blotting (Fig. 5A), microarray data (fold change = 6; Fig. 5B), and quantitative PCR assays (Fig. 5C). LBH589 also caused caspase-9 and caspase-3 cleavage, with generation of active low M, cleaved fragments, as well as PARP cleavage (Fig. 5A).

In addition to these biochemical studies, gene expression profiling uncovered another potential regulator of the apoptosome, termed AVEN. This protein acts as an inhibitor of the apoptosome by inhibiting caspase-9 activation (16). AVEN was down regulated (fold change = -13; Fig. 5B) by treatment with LBH589.

**Figure 2.** LBH589 causes death of patient cells with multiple myeloma and potentiates the antmyeloma action of bortezomib, dexamethasone, and melphalan. A, action of LBH589 in cells from patients with multiple myeloma. Patient cells were plated in six-well plates and treated with LBH589 at 10 and 100 nmol/L. After 18 hours, cells were stained with Annexin V-FITC and four monoclonal antibodies (CD38, CD56, CD28, and CD45), which allows the distinction between myeloma plasma cells and the remaining normal bone marrow cells, normal lymphocytes, and granulocytes. B, LBH589 (3 nmol/L) was combined with bortezomib (2 nmol/L), dexamethasone (1 μmol/L), or melphalan (2.5 μmol/L), and after 48 hours, MTT assays were done on MM1S cells. C, combination of LBH589 with bortezomib enhances cytotoxicity against patient multiple myeloma cells. Patient’s multiple myeloma cells were treated with LBH589 (10 nmol/L) and bortezomib (5 nmol/L) for 18 hours, and apoptosis was determined by staining with Annexin V-FITC.
Quantitative PCR analyses confirmed the decrease in AVEN expression, which was clearly evidenced at 12 hours (Fig. 5C).

The above data represented clear evidence that LBH589 triggered the activation of the intrinsic apoptotic pathway in multiple myeloma cells. To investigate the importance of this pathway in the antmyeloma action of LBH589, the ability of the caspase-3 inhibitor Z-VAD-FMK (30) to rescue from LBH589-induced cell death was evaluated. MM1S cells were preincubated for 60 minutes with Z-VAD-FMK, then LBH589 was added, and the incubations continued for 24 hours. As shown in Fig. 5D, preincubation with the caspase-3 inhibitor slightly blocked LBH589-induced cell death. In contrast, Z-VAD-FMK had a much higher inhibitory effect on the cell death caused by bortezomib, as previously described (31). These results indicated that although LBH589 activated the caspase-dependent apoptotic pathway, this activation was not the sole executor of cell death caused by the compound.

Other HDAC inhibitors, such as SAHA, have been shown to cause apoptotic cell death through caspase-independent routes (6). These alternative routes include mitochondrial release of the above mentioned proapoptotic factors AIF and endonuclease G, or activation of calcium-dependent proteases, such as calpain (30). To evaluate a potential role of calpain in the action of LBH589, MM1S cells were incubated with the calpain inhibitor calpeptin (50 nmol/L), and its effect on LBH589-induced cell death was analyzed at different times (24, 36, 48 hours). Calpeptin was unable to prevent LBH589-induced cell death, indicating that this effect of LBH589 does not involve activation of calpain (data not shown).

**Action of LBH589 on the extrinsic apoptotic pathway.** Recent reports have suggested that HDAC inhibitors may act through up-regulation of receptors and ligands of the Fas or tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) family, which are linked to the activation of the extrinsic apoptotic pathway (30). Treatment of MM1S cells with LBH589 failed to reveal substantial changes in the levels of Fas or its ligand, TRAIL, or its receptors (Fig. 5B and E; data not shown). Interestingly, however, the gene expression analyses identified a gene, termed TOSO, which showed a marked down-regulation (fold change = −90). This effect of LBH589 was confirmed by quantitative PCR.
As far as caspases are involved in the extrinsic apoptotic pathway, LBH589 provoked caspase-8 cleavage with generation of truncated fragments (Fig. 5F). In addition, cleavage of Bid with generation of its proapoptotic truncated form was also evidenced although at later times of LBH589 exposure (Fig. 5F).

**Overexpression of Bcl-X impairs LBH589-induced cell death.** Bcl-2 family members act as important regulators of mitochondrial outer membrane permeability (30). Microarray analyses indicated that LBH589 down regulated the Bcl-2 family members BCL2 (fold change = −2) and particularly BCLX (fold change = −170; Fig. 5B). Both Western blotting (Fig. 6A) and quantitative PCR (Fig. 5C) confirmed these results. Because Bcl-X displayed the higher gene disregulation, the possibility that restoration of its levels could affect LBH589 efficacy was analyzed. To this end, MM1S cells were infected with a retroviral vector that coded for an AU1 epitope-tagged version of Bcl-X. As shown in Fig. 6B, inclusion of the AU1 tag caused a retardation in the $M_r$ of AU1-Bcl-X, which allowed distinction from autogenous Bcl-X. MM1S cells expressing AU1-Bcl-X, in addition to endogenous Bcl-X, were more resistant to cell death than MM1S cells infected with the empty vector (Fig. 6C).

**Discussion**

HDAC inhibitors are a novel class of chemotherapeutic agents identified by their ability to induce apoptosis and inhibit the cell cycle (1, 2). We evaluated the effects of HDAC inhibition by LBH589 in cell lines and fresh tumor cells from patients with multiple myeloma. The effect of LBH589 on multiple myeloma cell lines was observed at an IC$_{50}$ in the low nmol/L range, close to that of bortezomib, and significantly lower than that observed for dexamethasone, melphalan, doxorubicin, reldamycin, and arsenic trioxide. This efficacy is superior to that of the related HDAC inhibitors SAHA (6, 13) and NVP-LAQ824 (14), whose action on myeloma cells occurs at micromolar concentrations. Moreover, LBH589 synergized with bortezomib, dexamethasone, and melphalan to decrease multiple myeloma cell number. In addition, analyses of apoptosis on fresh tumor cells from multiple myeloma patients showed that LBH589 had a similar antmyeloma activity to that found on multiple myeloma cell lines, and this was observed not only on plasma cells from untreated patients but also on patients with refractory disease. Moreover, using a multi-parametric flow cytometry approach, which allows the discrimination between myelomatous plasma cells and residual normal bone marrow cells, we observed that LBH589 cytotoxicity was very selective for tumor cells because only marginally affected bone marrow lymphocytes or granulocytes. Taken together, these data show that LBH589 has potent in vitro antmyeloma activity. Furthermore, the observed synergistic interaction between LBH589 and other antmyeloma compounds may translate into attractive combinations in the clinical setting.

Our studies on the mechanism of action of LBH589 indicate that this compound affects several routes involved in the control of cell cycle progression and apoptosis. LBH589 caused a progressive accumulation of cells in $G_0$-$G_1$ phases with a decrease in the percentage of cells in proliferative phases (S and G$_2$-M) in MM1S cells. Western blotting and microarray analyses indicated changes in the amounts of the Cip/Kip family of cell cycle regulators p21, p27, and p57. LBH589 caused an increase in the amount of p21. Induction of p21 has previously been shown to occur in multiple myeloma cells treated with other HDAC inhibitor, such as depsipeptide (11), NVP-LAQ824 (14), or SAHA (6, 13). Furthermore, p21 increases have been reported in leukemia cells treated with LBH589 (15). In addition, LBH589 also increased the levels of p53, an upstream transcriptional regulator of p21, and also increased p57 expression, a Cip/Kip family protein that arrests the cell cycle (33).

In addition to its effect on the cell cycle, LBH589 provoked cell death. Criteria for the latter include Annexin V positivity, an increase in the sub-$G_0$ region in cytometry studies, and DNA fragmentation. Analyses of the effect of LBH589 on multiple myeloma cells indicated that this compound caused cell death through mitochondrial perturbation. Progressive loss of the mitochondrial membrane potential reflected an increase in the permeability of the outer mitochondrial membrane, which allowed release of proapoptotic proteins, such as cytochrome $c$ or AIF. The former, together with caspase-9 and Apaf-1, interacts to create the apoptosome (29, 30). We have observed by oligonucleotide arrays,
reverse transcription-PCR, and Western blotting a significant increase in Apaf-1 expression following LBH589 treatment. In addition, LBH589 provoked caspase-9 activation/cleavage. In line with our observations, Mitsiades et al. (13) have also shown that Apaf-1 is up-regulated in multiple myeloma cells treated with SAHA. Recent elegant studies showing that SAHA-induced cell death can be prevented by Apaf-1 knock down add further evidence on the role of Apaf-1 in the mechanism of action of HDAC inhibitors (34). Microarray analyses, confirmed by quantitative PCR analyses of five genes that participate in the extrinsic apoptotic pathway. Representative of at least three independent experiments. D, effect of the pancaspase inhibitor Z-VAD-FMK on LBH589-induced cell death. MM1S cells were plated and pretreated where indicated, with Z-VAD-FMK (50 μmol/L) for 60 minutes. LBH589 (100 nmol/L) or bortezomib (10 nmol/L) were added to the corresponding samples, and the experiment was continued for 24 hours. MTT uptake was carried out as described above. E, gene expression data obtained by quantitative PCR analyses of five genes that participate in the extrinsic apoptotic pathway. Representative of at least three independent experiments. F, activation of caspase-8 and cleavage of Bid induced by LBH589. MM1S cells were treated as in (A), and the cleavage of caspase-8 and Bid was examined by Western blotting.

4 X. Carvajal-Vergara and A. Pandiella, unpublished data.
LBH589 seems different from that of SAHA, which is calpain dependent and caspase independent.

Recent studies have shown that AIF, together with endonuclease G, mediates cell death through a caspase-independent pathway (30). AIF translocates from the mitochondria to the cytosol, in transit to the nucleus, where it interacts with DNA and stimulates, together with endonuclease G, the formation of the degradosome (30). The latter complex mediates chromatid condensation, proteolysis, and DNA damage. We have shown that LBH589 induces translocation of AIF from the mitochondria to the cytosolic fraction, and this was concomitant with the release of cytochrome c to the cytosol. These data suggest that release of AIF may play a relevant role in cell death induced by LBH589.

Bcl-2 family members have been shown to regulate mitochondrial outer membrane permeability (29, 30). Western blotting, quantitative PCR, and microarray studies indicated that LBH589 down-regulated the antiapoptotic proteins Bcl-2 and Bcl-X. These data are in line with the down-regulation of the expression of Bcl-2 and Bcl-X reported with depsipeptide in multiple myeloma cell lines (11) and SAHA (6) in myeloma cells. In addition to the biochemical data, functional evidence indicated the important role of the interplay of Bcl-2 family members and mitochondria in the action of LBH589. Thus, when MM1S cells were infected with a retrovirus that coded for an epitope-tagged form of Bcl-X, therefore increasing the total amount of cellular Bcl-X, the apoptotic action of LBH589 was profoundly compromised.

In conclusion, LBH represents a novel hydroxamic acid–derived HDAC inhibitor with strong activity against multiple myeloma at nanomolar concentrations. LBH induced growth arrest and caspase-dependent and caspase-independent apoptosis. The action of LBH589 on resistant multiple myeloma cell lines and on fresh plasma cells from patients with refractory disease, together with its capacity to potentiate other anti-myeloma agents, would support the clinical evaluation of LBH589 in multiple myeloma.

Acknowledgments


Grant support: Spanish Association Against Cancer (A. Pandiella and J. San Miguel), International Myeloma Foundation (A. Pandiella and J. San Miguel), FIS-FEDER (A. Pandiella and J. San Miguel), Spanish Myeloma Network Program G03/136, Glaxo-Consorcio Superior de Investigaciones Científicas fellowship (X. Carvajal-Vergara), Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (I+D+i; E.M. Ocio), and Instituto de Salud Carlos III-Fondo de Investigación Sanitaria with expedient no. 400001 (E.M. Ocio).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Sheila Mateos-Dominguez for excellent technical assistance.

References


The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance

Patricia Maiso, Xonia Carvajal-Vergara, Enrique M. Ocio, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/66/11/5781

Cited articles
This article cites 34 articles, 16 of which you can access for free at:
http://cancerres.aacrjournals.org/content/66/11/5781.full#ref-list-1

Citing articles
This article has been cited by 37 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/66/11/5781.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/66/11/5781.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.